Overview

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Status:
NOT_YET_RECRUITING

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.

Phase:

PHASE1

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Cyclophosphamide
Interferons
peginterferon alfa-2b
pembrolizumab